Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Nature’s Bioceuticals Consummates the Purchase of Sinusitis Formula and Will Commence Sales

November 8, 2011

CAPE CORAL, Fla., Nov. 8, 2011 /PRNewswire/ — Nature’s Bioceuticals, a wholly owned subsidiary of Mistral Ventures, Inc. (MILV.pkNews) announced that it has consummated the purchase of the Sinusitis formula and now owns the exclusive rights to the formula. The company anticipates marketing the product under the name of Nature’s Sinus Relief Formula.

The Center for Disease Control and Prevention estimates that close to 31 million adults in the US suffer from chronic sinusitis, resulting in 12.5 million ambulatory care visits per year and more than 200,000 sinus surgical procedures every year. Acute sinusitis is even more common, though there are no good estimates for the number of people who experience an episode of acute sinusitis every year. Billions of dollars per year are wasted on doctor visits and antibiotics that are unnecessarily prescribed to treat viral infections for which they will not help. Our all natural product has been shown to provide relief in a few short days.

Robert deZanger, CEO of Nature’s Bioceuticals states “We are happy to now own the Sinus Relief Formula and are excited about bringing this product to market. We expect to have product manufactured and ready for sale in the next 30-60 days. The product should also have far reaching impact for the relief of nasal discomfort due to allergies and cold and flu. The cost to produce is nominal and therefore the profit margins will be large. We believe it will command a substantial market share in the three different markets therefore producing substantial revenues for the company. We anticipate sales in excess of $10,000,000.00 the first year and then expanding exponentially thereafter as the product gains market share.”

About Nature’s Bioceuticals:

Nature’s Bioceuticals develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. These medicines are all natural and derived from botanicals and mineral bases. Nature’s Bioceuticals strives to provide high quality natural medicines that are as effective, if not more effective, than synthetic drugs and more importantly do not have the negative side effects usually associated with many of today’s prescribed drugs.

Nature’s line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA, or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, commonly referred to as “DSHEA.”

In addition to historical information, this release contains forward-looking statements.

Mistral Ventures, Inc. and/or Nature’s Bioceuticals may, from time to time, make written or oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements encompass Mistral Ventures, Inc. and/or Nature’s Bioceuticals beliefs, expectations, hopes, or intentions regarding future events. Words such as “expects,” “intends,” “believes,” “anticipates,” “should,” “likely,” and similar expressions identify forward-looking statements. All forward-looking statements included in this release are made as of the date hereof and are based on information available to the Company as of such date. Neither Mistral Ventures, Inc. nor Nature’s Bioceuticals assume any obligation to update any forward-looking statement.

Actual results will vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of reasons, including, among others: further reviews of the Company’s financial statements by the Company and its Audit Committee; modification of the Company’s accounting practices; foreign business risks; industry cyclicality; fluctuations in customer demand and order pattern; changes in pricing and general economic conditions; as well as other risks that may be delineated from time to time or filed with the SEC.

Media Contact:
Financial Insights
Phone Number: 888 656 3509
E-mail: investors@naturesbioceuticals.com
www.naturesbioceuticals.com

SOURCE Mistral Ventures, Inc.


Source: PR Newswire